Back to results
US 2025/0084376 A1Published application
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
AssigneeMendus B.V.
InventorsErik Hans Manting, Jeroen Rovers, Satwinder Kaur Singh
Life of this patent
Estimating the term…
Abstract
The present disclosure provides ex vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy.
Claims21
1-123. (canceled)
A method for generating and/or expanding a population of immune cells with enhanced activation status, comprising:
- (a) obtaining a population of immune cells from a subject;
- (b) contacting the population of immune cells with a non-proliferating modified cell of leukemic origin having a mature dendritic cell phenotype;
- and
- (c) co-culturing the population of immune cells and the modified cell of leukemic origin under conditions suitable to expand and stimulate proliferation of the immune cells,
- thereby generating the population of immune cells with enhanced activation status, wherein the method results in multiplying the population of immune cells by at least 10 fold.
2 more elements
Dependencies are inferred from the claim text.